Rituximab treatment in pediatric-onset multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pediatric Medicine

Background:

• Rituximab (RTX) is widely used for multiple sclerosis (MS).
• Limited data exists on RTX efficacy and safety in pediatric-onset MS.
• Understanding RTX's risk-benefit profile in young MS patients is crucial.

Purpose of the Study:

• To evaluate the efficacy and safety of Rituximab (RTX) in pediatric-onset multiple sclerosis.
• To assess RTX's impact on clinical relapse rates and MRI activity.
• To determine the proportion of patients achieving no evidence of disease activity (NEDA-3).

Main Methods:

• Retrospective cohort study of 61 pediatric MS patients from Sweden, Austria, and Germany treated with RTX.
• Assessed annualized relapse rates, Expanded Disability Status Scale (EDSS), and MRI parameters (T2 lesions, contrast-enhancing lesions) pre- and post-treatment.
• Monitored adverse events, including infusion reactions and infections.

Main Results:

• RTX treatment led to a significant reduction in annualized relapse rates (0.6 to 0.03).
• MRI activity substantially decreased, with annual new T2 lesions dropping from 1.25 to 0.08 and contrast-enhancing lesions from 0.86 to 0.
• 70% of patients achieved NEDA-3; 67% experienced adverse events, with 6 discontinuing treatment.

Conclusions:

• Rituximab (RTX) demonstrates significant efficacy in reducing clinical and radiological disease activity in pediatric-onset multiple sclerosis.
• RTX is a viable treatment option for pediatric MS, offering substantial disease control.
• Careful monitoring for adverse events is recommended during RTX therapy in this population.